Fortrea Holdings Inc.
A global contract research organization that helps pharmaceutical, biotech, and medical device companies run clinical trials, from early safety studies to final-stage testing. Its roots stretch back to Covance and to a clinical business founded in 1968, and in 2023 it was spun off from the lab giant Labcorp to stand on its own. The name "Fortrea" is a made-up word from that split, likely blending "fortitude" and "trial" — a nod to the strength of the clinical studies it runs.
Granted 162.2K · Bought 73.5K
Granted 206.1K · Bought 30.0K · Sold 11.3K
Granted 120.2K · Sold 27.0K
Granted 114.8K · Sold 31.4K
Granted 62.8K · Bought 9.9K
Granted 52.5K
Granted 52.5K
Granted 52.5K
Granted 46.1K
Granted 32.2K · Sold 11.9K
Granted 24.2K · Bought 2.0K · Sold 4.9K
Granted 13.6K
Granted 6.4K
Granted 7.7K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Neupert Peter MDirector · 6 transactions | — | 246.7K | 162.2K | 73.5K | — |
| Pike ThomasChief Executive Officer, Director · 8 transactions | — | 159.9Kas of Jan 2025 | 206.1K | 30.0K | 11.3K |
| Mcconnell Jill G.Chief Financial Officer · 39 transactions | — | 78.4K | 120.2K | — | 27.0K |
| Morais Mark A.Chief Operating Officer · 46 transactions | — | 76.0K | 114.8K | — | 31.4K |
| Russell Erin LDirector · 3 transactions | — | 72.6K | 62.8K | 9.9K | — |
| Pesicka Edward ADirector · 3 transactions | — | 52.5K | 52.5K | — | — |
| Ray AmritDirector · 3 transactions | — | 52.5K | 52.5K | — | — |
| Smith David RossDirector · 6 transactions | — | 48.4K | 52.5K | — | — |
| Sanders MachelleDirector · 2 transactions | — | 46.1K | 46.1K | — | — |
| Eisenberg Glenn AExecutive Vice President, Director · 1 transaction | — | 42.2Kas of Jun 2023 | — | — | — |
| Parks RobertChief Accounting Officer · 8 transactions | — | 20.4K | 32.2K | — | 11.9K |
| Hanson James S.General Counsel · 10 transactions | — | 19.1K | 24.2K | 2.0K | 4.9K |
| Eckert R AndrewDirector · 2 transactions | — | 13.6Kas of Feb 2025 | 13.6K | — | — |
| van der Vaart Sandra DPresident and Secretary, Director · 1 transaction | — | 7.8Kas of Jun 2023 | — | — | — |
| Larson Betty DFormer Director · 1 transaction | — | 6.4Kas of Mar 2024 | 6.4K | — | — |
| Warren Amanda M.Chief Accounting Officer · 10 transactions | — | 5.3Kas of Jun 2024 | 7.7K | — | — |
| Pringle Robert S.Treasurer · 1 transaction | — | 1.3Kas of Jun 2023 | — | — | — |
| Laboratory Corp Of America Holdings10% owner · 1 transaction | — | 0as of Jun 2023 | — | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: +28.9K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.